If Biden weighs in, it will be a done deal. On another note, while I believe this trial will have moved the needle on the overall knowledge of GBM, it seems like we still have a lot to learn. So I hear that we are “matching” control and placebo patients, but are we really? We simply need to move the needle and go with the overall success rate. No trial reaches 20% blinded.
Market Data 
Markets 
AI
